ResultsIQ

ResultsIQ › Latest results › Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. Q3 FY26 earnings call summary

NSE: LALPATHLAB · BSE: 539524

Earnings call of 30 Jan 2026, summarised by AI from the filing.

Q3 FY26 revenue ₹660 cr (+10.6% YoY) with EBITDA margin 27.2%; management guides 11-12% organic growth and 27-28% EBITDA margin for the year.

Key takeaways

  1. Labour code One-time ₹30 cr cost reported as exceptional item, non-recurring, hit PBT and PAT.
  2. Swasthfit Contributed 26% to total revenue, scaling to Tier 2 and below towns for preventive testing.
  3. Seasonal fever Unexpected decline in seasonal fever portfolio lowered Q3 patient volume growth to 2.7%.

Original filing on BSE

Dr. Lal Path Labs Ltd. Q1 FY27 results

As filed: Revenue ₹798 cr (+19% year on year), EBITDA ₹248 cr (+28% year on year), PAT ₹171 cr (+27% year on year), EBITDA margin 31.0% (+222 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹703 cr (+17% year on year), EBITDA ₹187 cr (+11% year on year), PAT ₹132 cr (−15% year on year), EBITDA margin 26.6% (−128 bps). Score 44 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 128 bps year on year. Revenue rose ₹99.7 cr on a year ago, more than the ₹58.0 cr it added the year before. Share price after the results: +15.0% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹660 cr (+11% year on year), EBITDA ₹179 cr (+16% year on year), PAT ₹91.4 cr (+12% year on year), EBITDA margin 27.2% (+138 bps). Score 52 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was well below it. EBITDA margin rose 138 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue fell 10% from last quarter. Revenue rose ₹62.8 cr on a year ago, more than the ₹58.0 cr it added the year before. Share price after the results: −1.1% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹731 cr (+11% year on year), EBITDA ₹225 cr (+11% year on year), PAT ₹152 cr (+16% year on year), EBITDA margin 30.8% (+17 bps). Score 47 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 17 bps year on year. Profit rose ₹21.0 cr on a year ago, more than the ₹20.0 cr it added the year before. Share price after the results: −1.2% in 28 days (Nifty 500: +0.4%).
  • Q1 FY26: Revenue ₹670 cr (+11% year on year), EBITDA ₹193 cr (+14% year on year), PAT ₹134 cr (+24% year on year), EBITDA margin 28.8% (+57 bps). Score 51 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 57 bps year on year. Profit fell 14% from last quarter. Revenue rose ₹68.0 cr on a year ago, more than the ₹61.0 cr it added the year before. Share price after the results: +6.8% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹603 cr (+11% year on year), EBITDA ₹168 cr (+15% year on year), PAT ₹156 cr (+81% year on year), EBITDA margin 27.9% (+107 bps). Score 55 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well above it. EBITDA margin rose 107 bps year on year. Tax rate -1%. Revenue rose ₹58.0 cr on a year ago, more than the ₹54.0 cr it added the year before. Share price after the results: +2.2% in 28 days (Nifty 500: +2.7%).
  • Q3 FY25: Revenue ₹597 cr (+11% year on year), EBITDA ₹154 cr (+9% year on year), PAT ₹98.0 cr (+20% year on year), EBITDA margin 25.8% (−36 bps). Score 36 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 36 bps year on year. Revenue fell 10% from last quarter. Revenue rose ₹58.0 cr on a year ago, more than the ₹50.0 cr it added the year before.
  • Q2 FY25: Revenue ₹660 cr (+10% year on year), EBITDA ₹202 cr (+13% year on year), PAT ₹131 cr (+18% year on year), EBITDA margin 30.6% (+99 bps). Score 56 of 100, In line with trend. EBITDA margin rose 99 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Dr. Lal Path Labs Ltd. earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.